➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Baxter
McKinsey
Dow
Medtronic

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SACUBITRIL; VALSARTAN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sacubitril; Valsartan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02554890 comParIson Of Sacubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode Recruiting Novartis Pharmaceuticals Phase 4 2016-04-01 The purpose of this study is to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following hospitalization for acute decompensated heart failure (ADHF) and reduced ejection fraction (left ventricular ejection fraction (LVEF) ≤ 40%).
NCT02636283 Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Not yet recruiting American Heart Association Phase 2 2017-03-01 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02636283 Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease Not yet recruiting University of Minnesota - Clinical and Translational Science Institute Phase 2 2017-03-01 This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease, a condition caused by decreased blood flow to the muscles in the legs.
NCT02682719 ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation Recruiting Novartis Ireland Ltd Phase 2 2015-12-01 The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or diabetes or other risk factors for developing heart failure (elevated levels of natriuretic peptide and elevated left atrial volume index). Patients will be randomized to receive LCZ696 or valsartan (and matching placebo) for 18 months to assess the impact on left ventricular diastolic function.
NCT02682719 ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation Recruiting The Heartbeat Trust Phase 2 2015-12-01 The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or diabetes or other risk factors for developing heart failure (elevated levels of natriuretic peptide and elevated left atrial volume index). Patients will be randomized to receive LCZ696 or valsartan (and matching placebo) for 18 months to assess the impact on left ventricular diastolic function.
NCT02690974 Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting Recruiting Novartis Pharmaceuticals Phase 4 2016-03-01 The primary purpose of the study will be to describe the tolerability of treatment with the optimal dose of LCZ696 (97.2 mg sacubitril / 102.8 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection fraction (HFrEF) in Canada. The study will also describe the overall tolerability, effectiveness and safety of LCZ696 for the management of HFrEF over 12 months of treatment, as well as describe the patterns of LCZ696 up and down dose titrations occurring during the management of patients with HFrEF.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sacubitril; Valsartan

Condition Name

Condition Name for Sacubitril; Valsartan
Intervention Trials
Heart Failure 17
Heart Failure With Preserved Ejection Fraction 3
Heart Failure, Systolic 2
Myocardial Infarction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sacubitril; Valsartan
Intervention Trials
Heart Failure 35
Myocardial Infarction 4
Infarction 3
Hypertrophy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sacubitril; Valsartan

Trials by Country

Trials by Country for Sacubitril; Valsartan
Location Trials
United States 28
Canada 8
China 4
Greece 1
Ireland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sacubitril; Valsartan
Location Trials
Texas 3
Ohio 3
Pennsylvania 2
Minnesota 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sacubitril; Valsartan

Clinical Trial Phase

Clinical Trial Phase for Sacubitril; Valsartan
Clinical Trial Phase Trials
Phase 4 22
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sacubitril; Valsartan
Clinical Trial Phase Trials
Not yet recruiting 28
Recruiting 20
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sacubitril; Valsartan

Sponsor Name

Sponsor Name for Sacubitril; Valsartan
Sponsor Trials
Novartis Pharmaceuticals 15
Brigham and Women's Hospital 2
RenJi Hospital 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sacubitril; Valsartan
Sponsor Trials
Other 51
Industry 19
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Harvard Business School
McKesson
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.